TSE:MFC

Manulife Financial (MFC.TO)

61.42
+1.50 (2.50%)
as of Sep 3, 2026, 8:00:00 pm Market Open.
1632 watching
0
Investor Insights
star iconSep 3, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Manulife Financial (MFC) has garnered a mixture of opinions from analysts following its recent quarterly report, which showcased positive developments despite facing challenges such as a new tax on its products for mainland Chinese residents. The company is noted for its strong presence in Asia and steady growth in its wealth management segment, which remains a highlight in its long-term strategy. However, some experts express caution, labeling MFC as a bit overvalued relative to its earnings growth potential, currently trading over 2x book value. The financial landscape for insurers in Canada appears competitive, with both MFC and its peers like TD exhibiting relatively robust performance, yet the consensus leans toward a cautious approach due to market conditions. Overall, while MFC benefits from high dividends and solid asset management, uncertainties related to its exposure to market fluctuations warrant careful monitoring for potential entry points.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Fair Value
review icon
Similar
SLF
BUY
Likes all 3 insurance companies, Manulife, Sun Life and Great west Life. Feels they are set to increase their dividends. All excellent companies.
PAST TOP PICK
(A Top Pick Nov 15/04. Up 1.5%.) Not all synergies have been met on the John Hancock deal, so their is still some steam left. Try to buy in the $54 range which would give yoiu a return of 15%.
BUY
His favourite in the insurance industry and the overall financial sector.
BUY
A boring value style dividend paying stock, but where you end up with superior performance because a large portion of your return is from the dividends which are tax effective.
BUY
A good long term growth story in the financial sector. A dominant company in the index. Prefers over the banks.
BUY
Likes this company and the fee revenue they are generating. Probably a higher growth rate than with the banks.
BUY
Manulife and Sun Life have the capacity to increase their dividends more than the banks, which would be a good alternative to the banks.
DON'T BUY
The integration with John Hancock is going quite well. Too expensive. Would prefer 15/20% cheaper. Feels the street is too optimistic about their future profitability.
TOP PICK
Management has done a remarkable job in growing the company.Savings from the John Hancock takeover is going to be $325 million rather than $255 million. Could take over a bank down the road.
BUY
Likes both Sun Life and Manufacturers Life. Both have more room to increase their dividend payout ratio than the Cdn banks.
BUY
Has pulled back a little along with Cdn financials probably due to higher interest rate concerns. Not a bad entry point. Expects 10% upside including dividends. Very solid company.
BUY ON WEAKNESS
A very strong company. Can't see anything in the Eliot Spitzer investigation that will materially impact the company. Has a large US component, so some currency risk. Low $50's is a good entry point.
BUY ON WEAKNESS
Has been caught in a bit of a downdraft because of the bank reports. Asian operations are starting to fire. Wait until the banking reporting season is over and buy on dips.
BUY
Their #1 in the financial sector. Cash flow yield is 16%. Has a good growth potential with their John Hancock acquisition and their Asian activity. Well run.
WATCH
Currently evaluating. John Hancock acquisition was good. Latest quarterly earnings were disappointing. Expensive relative to other insurance companies but has a better growth profile.
Showing 1,966 to 1,980 of 2,284 entries